Hunan Jingfeng Pharmaceutical Co

Hunan Jingfeng Pharmaceutical Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Hunan Jingfeng Pharmaceutical Co (000908.SZ) as of Oct 25, 2026 is -2.80 %. In the previous year, Operating Cash Flow to Debt Ratio was 5.90 % — a change of -147.39% (lower).

OCF/Debt

-2.80 %

YoY

-147.39%

Last updated:

Operating Cash Flow to Debt Ratio of Hunan Jingfeng Pharmaceutical Co is 2024 -2.80 % . Operating Cash Flow to Debt Ratio of Hunan Jingfeng Pharmaceutical Co was 2023 5.90 % . It decreases by -147.39% lower compared to the previous year.

The Hunan Jingfeng Pharmaceutical Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2017
8.41 CNY
Jan 1, 2018
19.83 CNY
Jan 1, 2019
2.13 CNY
Jan 1, 2020
-19.09 CNY
Jan 1, 2021
14.18 CNY
Jan 1, 2022
20.59 CNY
Jan 1, 2023
5.90 CNY
Jan 1, 2024
-2.80 CNY
The Hunan Jingfeng Pharmaceutical Co OCF/Debt history
YEAROCF/DebtYoY
-2.80 %-147.39%
5.90 %-71.32%
20.59 %+45.21%
14.18 %-174.26%
-19.09 %-994.90%
2.13 %-89.24%
19.83 %+135.91%
8.41 %+1,250.00%
0.62 %-95.43%
13.64 %-64.50%
38.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hunan Jingfeng Pharmaceutical Co Stock analysis

What does Hunan Jingfeng Pharmaceutical Co do? Hunan Jingfeng Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical and biological drugs. Its main product categories include cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs, and anti-infective drugs. The company distributes these products domestically and also engages in commodity import and export trading, business management and consulting, and medical technology consulting services. Sales are primarily directed at the domestic market with no mention of international distribution channels. The firm's revenue streams are derived from pharmaceutical sales, particularly in cardiovascular, oncology, and infectious disease treatments, alongside ancillary services such as medical technology consulting. The domestic market remains the sole focus for product distribution, with no indication of export-oriented sales. The company's operations are centered on drug manufacturing and related consulting services, targeting healthcare providers and domestic consumers through established distribution networks. Hunan Jingfeng Pharmaceutical's business model emphasizes product diversity across multiple therapeutic areas, including cardiovascular, oncology, and infectious diseases. The company's revenue is driven by both direct pharmaceutical sales and ancillary consulting services, with all activities confined to the domestic market. The absence of international operations or export-focused strategies is consistent with the business description provided. Hunan Jingfeng Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hunan Jingfeng Pharmaceutical Co stock

Operating Cash Flow to Debt Ratio of Hunan Jingfeng Pharmaceutical Co is -2.80 % in 2024.

Operating Cash Flow to Debt Ratio of Hunan Jingfeng Pharmaceutical Co changed from 5.90 % to -2.80 %, representing a -147.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Hunan Jingfeng Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Hunan Jingfeng Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Hunan Jingfeng Pharmaceutical Co

All Key Metrics — Hunan Jingfeng Pharmaceutical Co